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A method has been developed and is described for the quantitative determination of a 
nonpeptide antithrombotic in dog plasma. The assay employs reversed phase microbore 
high-performance liquid chromatography in conjunction with tandem mass spectrometry 
utilizing pneumatically assisted electrospray ionization. The analyte and internal standard 
are isolated from the plasma matrix by solid-phase extraction. The mass spectrometer is 
operated in the positive ion multiple reaction monitoring mode and is set to detect the 
presence of a precursor-product ion pair for both the analyte and internal standard to 
generate product ion chromatograms for both species. The analyte is quantified by using 
weighted least-squares regression of the peak height ratio of drug:intemal standard. The 
method provides linear response for plasma concentrations ranging from 5 ng/mL (25 pg 
on-column) to 2500 ng/mL. Statistical evaluation and examples of authentic sample assays 
are also presented. 
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T here has recently been an increasing amount of attention given to fibrinogen receptor antago- nists as a means of treatment and/or prevention 
of thrombotic and thromboembolic ischemic events 
such as stroke and acute myocardial infarction. These 
compounds exhibit antithrombotic activity by disrupt- 
ing the platelet glycoprotein IIb-IIIa (GPIIb- 
IIIa)-fibrinogen interactions-hence preventing 
platelet aggregation and subsequent thrombus forma- 
tion. SB 214134 is a second-generation member in this 
class of compounds, employing a highly substituted 
benzodiazepine as the backbone of the molecule. To 
support preclinical pharmacokinetic characterization of 
the compound a rapid, sensitive, and specific assay 
was required for the quantification of SB 214134 in dog 
plasma. The molecule is not natively fluorescent, has a 
weak chromophore, is well retained on a reversed 
phase high-performance liquid chromatography 
(HJ?LC) system, and contains basic and acidic sites. In 
light of this, the use of high-performance liquid chro- 
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matography-tandem mass spectrometry (HPLC/ 
MS/MS) was pursued as the technique having the 
most potential of meeting all of the assay require- 
ments. 
The literature contains numerous examples of the 
use of high-performance liquid chromatography-mass 
spectrometry (HPLC/MS) in both qualitative [l-B] and 
quantitative [9-331 assays. The interface and ionization 
techniques used in these assays have included frit flow 
fast-atom bombardment [9, 101, particle beam [ll-13, 
261, and thermospray [14-171, with the use of atmo- 
spheric pressure chemical ionization (APCI) 11, 18-241 
and electrospray [2-B, 25-331 techniques becoming 
more widespread in some of the more recent applica- 
tions. The assays have achieved mass resolution by 
using both single [l, 2, 4-6, 9-15, 18-20, 26-311 and 
tandem [3, 7, 8, 16, 17, 21-25, 32, 331 mass spectrome- 
ters. All of these methods have demonstrated a high 
degree of sensitivity or selectivity for a variety of 
complex matrices, ranging from environmental [27] to 
physiological [l, 3, 4, 6, 9-16, 18-26, 28-30, 32, 331 
samples. 
Previous experience in our laboratory with com- 
pounds similar in structure to the present analyte 
indicated that the use of pneumatically assisted elec- 
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trospray ionization provided more stable performance, 
in terms of linearity and sensitivity, than was achiev- 
able by using APCI. Due to this prior in-house experi- 
ence and encouraged by the number of successful 
assays cited above, development of the current assay 
focused on the use of reversed phase microbore HPLC 
coupled to a triple quadrupole mass spectrometer uti- 
lizing pneumatically assisted electrospray ionization. 
This article describes the development and perfor- 
mance characterization of the resulting quantitative 
method. 
Experimental 
Materials 
The analyte (SB 214134) and an analog used as the 
internal standard (SB 213198) were obtained from the 
Department of Medicinal Chemistry (SmithKline 
Beecham). Their structures are shown in Figure 1. 
HPLC-grade water (Milli-Q water purification system; 
Millipore Corp., Bedford, MA) was used in the prepa- 
ration of all aqueous standard solutions and mobile 
phase. Reagent-grade formic acid was obtained from 
Sigma (St. Louis, MO) and reagent-grade trifluo- 
roacetic acid was supplied by Fluka (Ronkonkoma, 
NY). HPLC-grade acetonitrile and methylene chloride 
were purchased from J. T. Baker (Phillipsburg, NJ). 
Silica-based phenyl bonded phase solid-phase extrac- 
tion cartridges (100 mg/mL) were purchased from 
Analytichem International (Harbor City, CA). The 
solid-phase extraction vacuum manifold, equipped 
with Teflon needles, was obtained from Supelco (Be- 
llefonte, PA). 
Standards Sol 11 tions 
The stock solution of SB 214134 (1 mg/mL) and work- 
ing standard solutions at concentrations of 100, 10, 1, 
SB 214134 
b .CH3 
SB 213198 
Figure 1. Structures of (a) SB 214134 and (b) SB 213198 (internal 
standard). 
0.1, and 0.01 pg/mL were prepared in H,O. The 
aqueous stock solution of internal standard (1 mg/mL) 
was diluted appropriately to prepare the working in- 
ternal standard solution (4 pg/mL). These solutions 
were refrigerated for storage and were stable for at 
least 2 months. 
Sample Preparation 
A 100~PL aliquot of dog plasma, lo-50 PL of the 
appropriate aqueous working standard solution of SB 
214134 (to give the desired analyte concentrations if 
preparing calibration standards), and 50 PL of work- 
ing internal standard solution were briefly mixed in a 
12 x 75-mm glass culture tube. To this was added 500 
PL of an aqueous 0.1% trifluoroacetic acid solution, 
followed by another brief mixing. The sample was 
then transferred to a phenyl solid-phase extraction 
cartridge which had been conditioned with one col- 
umn volume of methanol and one column volume of 
aqueous 0.1% trifluoroacetic acid. By using vacuum, 
the sample was passed through the cartridge and the 
eluate was discarded. The cartridge was then sequen- 
tially washed with 1 mL each of (A) aqueous 0.1% 
trifluoroacetic acid, (B) aqueous 0.1% trifluoroacetic 
acid:acetonitrile (95:51, and (C) methylene chloride 
containing 0.1% trifluoroacetic acid. The isolated ana- 
lyte and internal standard were eluted from the car- 
tridge by using 1 mL of aqueous 0.1% trifluoroacetic 
acid:acetonitrile (1:l). The eluate was collected in a 
silanized 12 x 75-mm glass culture tube. The tube was 
placed in a water bath (approximately 45 ‘0 and the 
fraction was evaporated to dryness under a gentle 
stream of nitrogen. The resulting residue was reconsti- 
tuted with 100 PL of H,O and transferred to a low- 
volume insert in the I-IPLC autosampler vial. The vial 
was centrifuged briefly to precipitate any suspended 
insoluble material. 
High-Peuformance Liquid 
Chromatography-Tandem Mass Spectromety 
The HPLC system consisted of Hitachi L6200 and 
L6000 pumps (Danbury, CT), a model AS-3000 au- 
tosampler Uhermo Separation Products, Fremont, CA), 
and a SCIEX API III + mass spectrometer (Perkin- 
Elmer/Sciex, Ontario, Canada). The analytical micro- 
bore I-IPLC column was 50 X 1 mm, packed with 3-pm 
Hypersil BDS C,, material (Keystone Scientific, Belle- 
fonte, PA). The injection volume was set at 5 ILL. The 
mobile phase consisted of aqueous 0.1% formic 
acid:acetonitrile (85:15) and was delivered to the col- 
umn isocratically at a flow of 50 pL/min. The mass 
spectrometer was operated in the multiple reaction 
monitoring (MRM) mode by using ion-spray ionization 
with an ionization potential of 5500 V. The nebulizing 
gas (air) pressure was 40 lb/in.*, the curtain gas (N,) 
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flow was 1.6 L/min, and the orifice potential was 60 V. 
Ions were collisionally activated at an energy of 50 eV 
and the collision gas (Ar) thickness was 125 X 1013 
atoms/cm*. To assay for SB 214134, the mass spec- 
trometer was operated at unit mass resolution and set 
to select the [M + HI+ ion at m/z 429 for SB 214134 
and the [M + H]+ ion at m/z 403 for the internal 
standard (SB 213198) via the first quadrupole mass 
filter (Ql) while signals for product ions at m/z 261 
for both the analyte and internal standard were moni- 
tored via the third quadrupole mass filter (Q3). The 
dwell time for each transition was 200 ms. Multiple 
reaction monitoring data was acquired by using Mac- 
Spec version 3.22 and RAD version 2.5 software and 
integrated by using MacQuan version 1.3 software 
packages (Perkin-Elmer/Sciex). Under the conditions 
described, SB 214134 and the internal standard were 
not chromatographically resolved, with each having a 
retention time of approximately 1.2 min. 
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By using the analyte and internal standard working 
solutions described above, a series of plasma samples 
were prepared having drug concentrations of 0, 5, 10, 
30,50,100,300,500,1000,1500,2000, and 2500 ng/mL. 
These samples were subjected to the solid-phase ex- 
traction procedure to generate a 12 point standard 
curve. The chromatographic peak height ratios of 
product ions for drug and internal standard (drug:in- 
temal standard) were obtained, weighted by a factor of 
l/x (based on analysis of residuals), and plotted ver- 
sus the plasma drug concentrations. Linear regression 
analysis gave a calibration curve that was used to 
calculate plasma analyte concentrations. 
0 ” *- 4 - .’ ‘I 
150 200 250 300 350 400 
MASS/CHARGE (m/z) 
Figure 2. Positive ion ion-spray spectra of SB 214134: (al full- 
scan spectrum; (b) product ion spectrum. 
Precision Samples 
spectra for the internal standard are shown in Figure 
3a and b, respectively. As seen in the spectra, although 
the precursor ions are different for analyte and internal 
standard, both compounds generate the same product 
ion at m/z 261 produced by cleavage at the amide 
bond linking the benzodiazepine moiety of the 
molecules to the bipiperidine or piperidine compo- 
nents. 
Precision plasma samples were prepared by using a 
stock analyte solution prepared from a different ana- 
lyte weighing than was used to prepare standards for 
construction of the calibration curve. Plasma precision 
samples were prepared in bulk at each of six concen- 
tration levels (5, 10, 20, 1000, 2000, and 2500 ng/mLl. 
The bulk plasma samples at each level were then 
subdivided and aliquots were placed into individual 
tubes and frozen until the time of processing. Six 
replicates of each concentration level were processed 
and assayed on each of three days to obtain statistical 
data concerning the assay reproducibility. 
Under the conditions described, no chromato- 
graphic resolution is achieved between the analyte and 
internal standard. Both components coelute at a reten- 
tion time of approximately 1.2 min. However by utiliz- 
ing the mass resolution achieved, the extracted prod- 
uct ion chromatograms can easily differentiate be- 
tween the two components. 
Selectivity, Sensitivity, and Linearity 
Results and Discussion 
Compound Spectra and Resolution 
The positive ion full-scan ion-spray spectrum for the 
analyte and the corresponding product ion spectrum 
obtained from the [M + HI+ precursor are illustrated 
in Figure 2a and b, respectively. The corresponding 
Typical chromatograms obtained from selected moni- 
toring of the precursor to product ion for extracts of 
control dog plasma and plasma spiked with internal 
standard only are illustrated in Figures 4 and 5, respec- 
tively. These results demonstrate the high degree of 
selectivity and lack of interference from any endoge- 
nous components as well as any analyte-internal stan- 
dard interferences. 
In any quantitative method, sensitivity is a major 
factor to consider, especially when dealing with lim- 
ited sample sizes. The current assay employs various 
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Figure 3. Positive ion ion-spray spectra of SB 213198 (internal 
standard): (a) full-scan spectrum; (b) product ion spectrum. 
1.5 2.0 2.5 3.0 
TIME ,*, 
Figure 5. Chromatograms derived from selected monitoring of 
the precursor to product ion fragmentation for dog plasma spiked 
with internal standard only: (a) SB 214134; (b) SB 213198 (internal 
standard). 
techniques to enhance the sensitivity obtained. Many 
reported HPLC/MS electrospray methods utilize larger 
diameter Hl?LC columns (2 2 mm) and correspond- 
ingly higher mobile phase flow rates (> 200 pL/min), 
necessitating the use of a postcolumn splitter to reduce 
the flow rate of the mobile phase entering the mass 
spectrometer interface to approximately 50 pL/min 
14-7, 28-331 so as not to adversely impact the sensitiv- 
ity. Since the electrospray interface is typically consid- 
ered to act as a concentration-dependent detector, such 
an approach can successfully be used, provided pro- 
portionately more analyte is injected on-column as the 
column diameter increases. This increase is propor- 
tional to the ratio of the column diameters squared. 
Hence, if the column diameter is increased by a factor 
of 2, then the amount of analyte injected must be 
quadrupled to give the same detector response. How- 
ever when dealing with limited-volume samples, as is 
often the case in preclinical metabolism studies, such 
an approach may not be the most effective strategy. By 
utilizing a small-diameter (l-mm) microbore column, 
as in the current method, proportionately less analyte 
is required to be injected on-column to achieve the 
same sensitivity due to the concentration-dependent 
behavior of the electrospray process. In addition to 
reduced sample consumption, no postcolumn splitter 
is required, since 1-mm-i.d. columns can be operated 
very efficiently at near-optimum performance with a 
s 
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Figure 4. Chromatograms derived from selected monitoring of 
the precursor to product ion fragmentation for blank dog plasma: 
(a) SB 214134; (b) SB 213198 (internal standard). 
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mobile phase flow rate of 50 pL/min. Thus all of the 
injected analyte is used to generate signal, with none 
being wasted by diversion through a postcolumn split- 
ter such as occurs with the use of larger diameter 
chromatographic columns and their associated higher 
flow rates. 
Table 1. Recovery of SB 214134 and internal standard 
from dog plasma 
Compound 
Cont. 
(ng/mL) 
Mean 
recovery 
1%) 
cv 
(%I N 
Another feature to enhance sensitivity in the current 
method is the use of on-column focusing of the ana- 
lyte. For 1-mm-i.d. columns, especially those of short 
length as used here (5 cm), a 5-PL injection volume is 
unusually large and would typically lead to chromato- 
graphic band distortion and/or splitting. However by 
reconstituting the extract residue in a very weak sol- 
vent (100% aqueous) relative to the elution strength of 
the mobile phase (85% aqueous/l5% organic) larger 
injection volumes may be employed, with the analyte 
being retained and focused in a very narrow band at 
the column head. This is essentially on-column enrich- 
ment during the injection process, with very little 
migration occurring until after the injection process is 
completed. The result is a substantially larger analyte 
load than would typically be achieved, accompanied 
by very good chromatographic peak shape, effectively 
improving the sensitivity of the assay. 
SB 214134 5 94.69 8.27 6 
1000 98.01 10.70 6 
2500 90.24 11.61 6 
Internal 
standard 2000 84.44 17.35 6 
‘Coefficient of variation. 
the use of silanized glassware improved analyte and 
internal standard recovery from the dried solid-phase 
extraction residue. However, the use of silanized glass- 
ware was not necessary in either the initial spiking 
procedure or in the autosampler vials. 
Assay Statistics 
Utilizing the above techniques and operating the 
mass spectrometer in the MRh4 mode monitoring the 
analyte precursor-product ion pair of m/z 429/261, 
an on-column limit of detection (at a signal-to-noise 
ratio of 3) for the analyte was 2 ng/mL (10 pg on-col- 
umn; 23 fmol). Based on the described sample prepara- 
tion procedure and a 5-PL injection volume, linear 
response for the quantitative determination of analyte 
was obtained for plasma SB 214134 concentrations 
ranging from 5 ng/mL (25 pg on-column) to 2500 
ng/mL (12.5 ng on-column). Correlation coefficients 
obtained by using weighted (l/x) linear regression 
analysis were typically 0.997 or better. 
Table 2 presents the statistical results obtained during 
a 3-day assay validation. As seen in the table, the assay 
performs very well across the entire concentration 
range, with both the within-day and between-day as- 
a 4291261 
Recove y 
In any quantitative assay, the recovery of the analyte 
should be verified across the concentration range of 
the assay. Quantitative recovery is not necessarily a 
prerequisite for a successful quantification assay, al- 
though higher analyte recovery generally translates to 
better assay sensitivity. However, consistent analyte 
recovery across the concentration range is essential to a 
successful assay. Inconsistent recoveries may lead to a 
series of problems such as nonlinear response or poor 
assay reproducibility. The recovery data for analyte 
across the assay concentration range, as well as that for 
the internal standard, are summarized in Table 1. These 
values (mean of six replicates at each level) represent 
the amount of analyte determined to be present in 
extracted plasma samples spiked to the specific analyte 
concentrations relative to unextracted standards. Re- 
covery of the analyte is consistently high (> 90%) 
across the range, with a slightly lower recovery ob- 
served for the internal standard. Data indicated that 
1.5 2.0 2.5 3.0 
TIME Imir!) 
b lW- 145 4291261 
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Figure 6. Chromatograms derived from selected monitoring of 
the precursor to product ion fragmentation for SB 214134 follow- 
ing IV infusion administration to the dog; (a) End of infusion 
(1928 ng/mL); (b) later sample time (9 ng/mL). 
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Table 2. Summary of assay precision and accuracy 
Nominal 
cont. 
(ng/mL) Day 1 Day 2 Day 3 
Average Between- 
within-run run Average 
precisiona precisionb(%) accuracy”(%) 
5 8.68 4.73 101 .o 
Mean 
Std. dev. 
%CV 
% Accy. 
10 
Mean 
Std. dev. 
%CV 
% Accy. 
20 
Mean 
Std. dev. 
% cv 
% Accy. 
1000 
Mean 
Std. dev. 
% cv 
% Accy. 
2000 
Mean 
Std. dev. 
% cv 
% Accy. 
2500 
Mean 
Std. dev. 
% cv 
% Accy. 
4.79 5.12 5.25 
0.46 0.49 0.36 
9.61 9.50 6.93 
95.7 102.3 105.0 
9.79 9.83 10.03 
0.95 0.91 0.89 
9.69 9.23 8.84 
97.9 98.3 100.3 
20.06 19.06 19.53 
1.67 1.46 1.90 
8.31 7.68 9.71 
100.3 95.3 97.6 
965.56 1061.54 994.30 
66.00 35.98 87.87 
6.84 3.39 8.84 
96.6 106.2 99.4 
2054.70 1902.56 1975.89 
126.99 167.03 145.34 
6.18 8.78 7.36 
102.7 95.1 98.8 
2489.70 2563.08 2526.25 
110.05 100.53 96.40 
4.42 3.92 3.82 
99.6 102.5 101.1 
9.25 1.31 98.8 
8.57 2.57 97.8 
6.35 4.89 100.7 
7.44 3.85 98.9 
4.05 1.45 101.1 
‘Average within-run precision 1%) = (CV,,,, + CVrunl + CV,,,,)/number of runs. 
bBetween-run precision (%I= (std. dev. of within-day means x lOO)/average within-day mean. 
‘Average accuracy (o/.1 = (accuracy,,,, + accuracyrun + accuracy,,,a)/number of runs. 
say precision I 10% in all cases. The accuracy is also 
acceptable across the concentration range, varying from 
97.8 to 101.1%. The use of peak height ratios rather 
than peak area ratios resulted in marginally better 
statistical performance. 
Authentic Examples 
The described method has been applied to dog plasma 
samples for quantification of the analyte following 
administration of the compound via various dosing 
regimens. Figure 6a shows the chromatogram obtained 
from selected monitoring of the analyte precursor to 
product ion for an extract of a plasma sample obtained 
immediately following an intravenous infusion admin- 
istration of the drug to a dog. The plasma drug concen- 
tration in this sample was determined to be nearly 
2000 ng/mL. Figure 6b shows the chromatogram ob- 
tained from selected monitoring of the analyte precur- 
sor to product ion obtained for the extract of a plasma 
sample obtained from the same dog at a significantly 
later time point. The plasma analyte concentration for 
this sample was still quantifiable and determined to be 
less than 10 ng/mL. These two figures demonstrate 
the utility of a method having both a wide linear 
response range as well as adequate sensitivity. This 
method has been successfully used to generate plasma 
drug concentration versus time profiles of the analyte 
following a variety of dosing regimens, with each 
study consisting of approximately loo-150 samples, 
allowing for the rapid generation of quantitative data 
used for the subsequent pharmacokinetic characteriza- 
tion of the drug’s performance in the dog model. 
Conclusions 
In conclusion, the assay described is rapid, with chro- 
matographic elution of the analyte and internal stan- 
dard complete in less than 2 mm. The assay is selec- 
1244 SlMPSON 
tive, with no evidence of any interferences. The linear 
response range for quantification is from 5 ng/mL (25 
pg on-column) to 2500 ng/mL (12.5 ng on-column), 
with a limit of detection of 2 ng/mL (10 pg on- 
column). The assay is based on easily obtainable sam- 
ple volumes, and statistical evaluation proved the 
method to be reliable over the concentration range 
described. Finally, the method has successfully been 
applied to preclinical pharmacokinetic studies. 
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